Buprenorphine And Naloxone Tablet
FDA Label NDC 62175-458

59 label sections · Submitted to the FDA by Lannett Company, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Lannett Company, Inc. for the product Buprenorphine And Naloxone (NDC 62175-458). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 important dosage and administration information, 2.2 patient access to an opioid overdose reversal agent for the emergency treatment of opioid overdose, 2.3 maintenance, 2.4 method of administration, 2.5 clinical supervision, 2.6 unstable patients, 2.7 discontinuing treatment, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.